Roivant Sciences Ltd.
ROIV- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001635088
Insider trades, last 90 days
0 buys · 13 sells
- Sold $242.08M
- Open-market purchases (P) and sales (S), counted by Form 4 filing.
13F holders, Q2 2026
500
- +55 vs. Q1 2026
- Total value $20B
Superinvestors holding ROIV
3
- At the end of Q2 2026
Price chart
Latest insider trades
View all: Latest insider tradesOpen-market purchases and sales by ROIV insiders, newest first.
| Filed (ET) | Trade date | Insider | Transaction | Shares | Avg price | Value | Shares after | Holding change | Filing |
|---|---|---|---|---|---|---|---|---|---|
| Sep 17, 20266:43 PM ET | Sep 15, 2026 | Epperly Melissa B,Director | SSaleCommon Shares | −4.94K | $39.7387 | −$196.23K | 9.9K | −33.3% | SEC10b5-1 |
| Sep 17, 20266:42 PM ET | Sep 15, 2026 | Fitzgerald MeghanDirector | SSaleCommon Shares | −5.11K | $39.7403 | −$203.15K | 36.11K | −12.4% | SEC10b5-1 |
| Sep 10, 20269:00 PM ET | Sep 8, 2026 | Fitzgerald MeghanDirector | SSaleCommon Shares | −20K | $39.90 | −$798K | 42.96K | −31.8% | SEC10b5-1 |
| Sep 1, 20269:00 PM ET | Aug 28, 2026 | Venker EricPresident & Immunovant CEO | SSaleCommon Shares | −200K | $35.767 | −$7.15M | 1.6M | −11.1% | SEC10b5-1 |
| Aug 21, 20269:00 PM ET | Aug 19 – Aug 21, 2026 | Sukhatme MayukhPresident & CIO | SSaleCommon Shares | −335.17K | $36.8788 | −$12.36M | 18.63M | −1.8% | SEC |
Top 5 13F holders, Q2 2026
View all: Top 5 13F holders, Q2 2026The largest institutional positions in ROIV at the end of Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 81,020,390 | $2.87B | 0.12% | +3,039,137+3.9% | Added |
| BlackRock, Inc. | 48,236,091 | $1.71B | 0.03% | +3,981,831+9.0% | Added |
| MORGAN STANLEY | 42,592,905 | $1.51B | 0.08% | −9,235,420−17.8% | Reduced |
| QVT Financial LP | 23,723,074 | $839.56M | 53.73% | −1,438,163−5.7% | Reduced |
| VANGUARD CAPITAL MANAGEMENT LLC | 22,123,198 | $782.94M | 0.02% | +1,442,626+7.0% | Added |